Progressive Retinal Atrophy (PRA-RCD3) and the Newfoundland: How to Read a Genetic Test

Retinal degeneration is not one disease with one cause. It is an outcome that can be produced by mutations in many different genes, and different breeds carry different mutations. When researchers identify the exact mutation causing the condition in a particular breed, a laboratory can build a test that looks for that specific change in the DNA sequence.

That test is exquisitely accurate at one job: reporting whether this dog carries that particular variant. It is completely blind to everything else. A dog whose retinal degeneration is caused by a different mutation will test clear, and the result will be technically correct and clinically useless.

This is why a variant test carries a breed context. A mutation identified and validated in one breed may be absent from another breed's population entirely. Running such a test on a dog from an unrelated breed usually produces a clear result that was almost guaranteed before the swab was taken.

Commercial multi-breed panels test for many variants at once, which is convenient but generates a long list of clear results whose significance varies enormously. Some of those clears are meaningful; many are simply confirming the absence of something that was never plausible in that breed.

The practical rule is to ask, for any test result, whether that variant is known to occur in this breed. If it is not, the result is noise.

Most misunderstandings about DNA panels come from treating clear as a general clean bill of health rather than as a narrow, specific statement.

The Newfoundland's documented health issues are hip dysplasia, subaortic stenosis, dilated cardiomyopathy, cystinuria and bloat. Of those, cystinuria is the one where a DNA test has a clear and direct role, because it is a specific inherited transport defect and its detection changes both breeding decisions and lifelong management for an affected dog.

The cardiac conditions are heritable but are not screened by a swab in the way a single-gene disorder is. Subaortic stenosis and dilated cardiomyopathy are assessed by examination and imaging, which is why cardiac clearances involve a stethoscope and an ultrasound rather than a cheek sample.

Hip dysplasia is influenced by many genes and by growth environment, so it is assessed by radiographic screening rather than by DNA. Bloat is not a single-gene condition at all and is managed by risk reduction rather than by testing.

So the honest ranking for a Newfoundland buyer or breeder is that a cystinuria test, radiographic hip screening and a cardiac examination by an appropriately qualified veterinarian carry real weight. A broad commercial DNA panel returning dozens of clears for variants found in other breeds carries very little, however impressive the certificate looks.

What a panel can offer is a starting point for a conversation with your veterinarian. What it cannot offer is a substitute for the screening that this breed actually needs.